Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
5,167
archived clinical trials in
Liver Cancer

Prospective Tumor Response Evaluation
Prospective Evaluation of Tumor Response to Cancer Treatment Therapies
Status: Enrolling
Updated:  12/31/1969
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Prospective Tumor Response Evaluation
Prospective Evaluation of Tumor Response to Cancer Treatment Therapies
Status: Enrolling
Updated: 12/31/1969
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
Phase I/II Dose Escalation, Pharmacokinetic, Safety, and Efficacy Study of Oral TAC-101 in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
TAC-101 in Treating Patients With Advanced Hepatocellular Carcinoma (Liver Cancer)
Phase I/II Dose Escalation, Pharmacokinetic, Safety, and Efficacy Study of Oral TAC-101 in Patients With Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center at University of Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Heat Therapy in Treating Patients With Unresectable Primary or Metastatic Liver Cancer
A Phase II Study of Radiofrequency Ablation of Unresectable Liver Tumors
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Heat Therapy in Treating Patients With Unresectable Primary or Metastatic Liver Cancer
A Phase II Study of Radiofrequency Ablation of Unresectable Liver Tumors
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
TREATMENT OF CHILDREN AND YOUNG ADULTS WITH RECURRENT/REFRACTORY SOLID TUMORS WITH HIGH DOSE ETOPOSIDE AND CARBOPLATIN PLUS ESCALATING DOSE CYCLOPHOSPHAMIDE, FOLLOWED BY HEMATOPOIETIC RESCUE USING AUTOLOGOUS CD34+ SELECTED BLOOD STEM CELLS: A PILOT STUDY
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Oncology Center
mi
from
Baltimore, MD
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
TREATMENT OF CHILDREN AND YOUNG ADULTS WITH RECURRENT/REFRACTORY SOLID TUMORS WITH HIGH DOSE ETOPOSIDE AND CARBOPLATIN PLUS ESCALATING DOSE CYCLOPHOSPHAMIDE, FOLLOWED BY HEMATOPOIETIC RESCUE USING AUTOLOGOUS CD34+ SELECTED BLOOD STEM CELLS: A PILOT STUDY
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Oncology Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Non-Randomized Study of Internal Radiation Therapy to the Liver in Patients With Primary Liver Cancer for Whom Surgery is Not Possible.
Treatment of Unresectable Hepatocellular Carcinoma With Therasphere. A Human Device Evaluation Protocol.
Status: Enrolling
Updated:  9/7/2005
St. Joseph's Hospital
mi
from
Tampa, FL
A Non-Randomized Study of Internal Radiation Therapy to the Liver in Patients With Primary Liver Cancer for Whom Surgery is Not Possible.
Treatment of Unresectable Hepatocellular Carcinoma With Therasphere. A Human Device Evaluation Protocol.
Status: Enrolling
Updated: 9/7/2005
St. Joseph's Hospital
mi
from
Tampa, FL
Click here to add this to my saved trials
A Clinical Study of GP73 as a Hepatocellular Carcinoma (HCC) Tumor Mark
A Clinical Study of GP73 as a HCC Early Tumor Mark
Status: Enrolling
Updated:  5/14/2009
University of Chicago
mi
from
Chicago, IL
A Clinical Study of GP73 as a Hepatocellular Carcinoma (HCC) Tumor Mark
A Clinical Study of GP73 as a HCC Early Tumor Mark
Status: Enrolling
Updated: 5/14/2009
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors
Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors
Status: Enrolling
Updated:  8/6/2009
Norton Healthcare
mi
from
Louisville, KY
Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors
Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors
Status: Enrolling
Updated: 8/6/2009
Norton Healthcare
mi
from
Louisville, KY
Click here to add this to my saved trials
Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors
Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors
Status: Enrolling
Updated:  8/6/2009
University of Louisville Hospital
mi
from
Louisville, KY
Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors
Evaluation of Intra-operative Ultrasound Contrast Enhancement in the Evaluation of Liver Tumors
Status: Enrolling
Updated: 8/6/2009
University of Louisville Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)
TheraSphere HUD For Treatment of Unresectable HCC
Status: Enrolling
Updated:  1/12/2010
University of Louisville Hospital / Norton Hospital
mi
from
Louisville, KY
TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)
TheraSphere HUD For Treatment of Unresectable HCC
Status: Enrolling
Updated: 1/12/2010
University of Louisville Hospital / Norton Hospital
mi
from
Louisville, KY
Click here to add this to my saved trials
Feasibility of Using Real-time Cine-MRI for Treating Moving & Deforming Tumors
Investigating the Feasibility of Using Real-time Cine-MRI for Treating Moving and Deforming Tumors
Status: Enrolling
Updated:  6/24/2010
Stanford University School of Medicine
mi
from
Stanford, CA
Feasibility of Using Real-time Cine-MRI for Treating Moving & Deforming Tumors
Investigating the Feasibility of Using Real-time Cine-MRI for Treating Moving and Deforming Tumors
Status: Enrolling
Updated: 6/24/2010
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor
Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor: a Phase I Study
Status: Enrolling
Updated:  7/13/2010
Penn State Hershey Medical Center
mi
from
Hershey, PA
Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor
Treatment of Unresectable Hepatocellular Cancer With Opioid Growth Factor: a Phase I Study
Status: Enrolling
Updated: 7/13/2010
Penn State Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Measurement of Pro-antiangiogenic Markers in Patients With Hepatic Metastases Undergoing Selective Internal Radiation Therapy (SIRT)
Measurement of Pro-antiangiogenic Markers in Patients With Hepatic Metastases Undergoing Selective Internal Radiation Therapy (SIRT)
Status: Enrolling
Updated:  7/20/2010
Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
Measurement of Pro-antiangiogenic Markers in Patients With Hepatic Metastases Undergoing Selective Internal Radiation Therapy (SIRT)
Measurement of Pro-antiangiogenic Markers in Patients With Hepatic Metastases Undergoing Selective Internal Radiation Therapy (SIRT)
Status: Enrolling
Updated: 7/20/2010
Robert Wood Johnson University Hospital
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Measurement of Pro-antiangiogenic Markers in Patients With Hepatic Metastases Undergoing Selective Internal Radiation Therapy (SIRT)
Measurement of Pro-antiangiogenic Markers in Patients With Hepatic Metastases Undergoing Selective Internal Radiation Therapy (SIRT)
Status: Enrolling
Updated:  7/20/2010
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Measurement of Pro-antiangiogenic Markers in Patients With Hepatic Metastases Undergoing Selective Internal Radiation Therapy (SIRT)
Measurement of Pro-antiangiogenic Markers in Patients With Hepatic Metastases Undergoing Selective Internal Radiation Therapy (SIRT)
Status: Enrolling
Updated: 7/20/2010
The Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
RAD001 in Advanced Hepatocellular Carcinoma
A Phase I/II Study of RAD001 in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/22/2010
Massachusetts General Hospital
mi
from
Boston, MA
RAD001 in Advanced Hepatocellular Carcinoma
A Phase I/II Study of RAD001 in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/22/2010
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
RAD001 in Advanced Hepatocellular Carcinoma
A Phase I/II Study of RAD001 in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/22/2010
Dana-Farber Cancer Institute
mi
from
Boston, MA
RAD001 in Advanced Hepatocellular Carcinoma
A Phase I/II Study of RAD001 in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/22/2010
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
RAD001 in Advanced Hepatocellular Carcinoma
A Phase I/II Study of RAD001 in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated:  7/22/2010
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
RAD001 in Advanced Hepatocellular Carcinoma
A Phase I/II Study of RAD001 in Advanced Hepatocellular Carcinoma
Status: Enrolling
Updated: 7/22/2010
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox® (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma
Status: Enrolling
Updated:  6/7/2011
UCLA
mi
from
Los Angeles, CA
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox® (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma
Status: Enrolling
Updated: 6/7/2011
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox® (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma
Status: Enrolling
Updated:  6/7/2011
Mayo Clinic - Jacksonville, Florida
mi
from
Jacksonville, FL
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox® (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma
Status: Enrolling
Updated: 6/7/2011
Mayo Clinic - Jacksonville, Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox® (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma
Status: Enrolling
Updated:  6/7/2011
University of Louisville
mi
from
Louisville, KY
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox® (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma
Status: Enrolling
Updated: 6/7/2011
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox® (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma
Status: Enrolling
Updated:  6/7/2011
Mayo Clinic Rochester
mi
from
Rochester, MN
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox® (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma
Status: Enrolling
Updated: 6/7/2011
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox® (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma
Status: Enrolling
Updated:  6/7/2011
Mount Sinai School of Medicine
mi
from
New York, NY
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox® (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma
Status: Enrolling
Updated: 6/7/2011
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox® (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma
Status: Enrolling
Updated:  6/7/2011
Cleveland Clinic
mi
from
Cleveland, OH
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox® (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma
Status: Enrolling
Updated: 6/7/2011
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox® (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma
Status: Enrolling
Updated:  6/7/2011
Temple University Hospital
mi
from
Philadelphia, PA
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox® (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma
Status: Enrolling
Updated: 6/7/2011
Temple University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox® (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma
Status: Enrolling
Updated:  6/7/2011
Geisinger Health System
mi
from
Wilkes Barre, PA
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox® (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma
Status: Enrolling
Updated: 6/7/2011
Geisinger Health System
mi
from
Wilkes Barre, PA
Click here to add this to my saved trials
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox® (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma
Status: Enrolling
Updated:  6/7/2011
University of Texas Health Science Center
mi
from
San Antonio, TX
Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)
A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox® (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma
Status: Enrolling
Updated: 6/7/2011
University of Texas Health Science Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
Single Arm, Non Randomized Phase II Trial of Gemcitabine and Oxaliplatin (GEM-OX) for Hepatocellular Carcinoma (HCC) Patients With Platelet Counts Greater Than 100,000 Per Microliter.
Status: Enrolling
Updated:  9/23/2011
Hematology Oncology Associates, PC
mi
from
Albuquerque, NM
Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
Single Arm, Non Randomized Phase II Trial of Gemcitabine and Oxaliplatin (GEM-OX) for Hepatocellular Carcinoma (HCC) Patients With Platelet Counts Greater Than 100,000 Per Microliter.
Status: Enrolling
Updated: 9/23/2011
Hematology Oncology Associates, PC
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
Single Arm, Non Randomized Phase II Trial of Gemcitabine and Oxaliplatin (GEM-OX) for Hepatocellular Carcinoma (HCC) Patients With Platelet Counts Greater Than 100,000 Per Microliter.
Status: Enrolling
Updated:  9/23/2011
Lovelace Sandia Health Systems Dept of Hematology
mi
from
Albuquerque, NM
Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
Single Arm, Non Randomized Phase II Trial of Gemcitabine and Oxaliplatin (GEM-OX) for Hepatocellular Carcinoma (HCC) Patients With Platelet Counts Greater Than 100,000 Per Microliter.
Status: Enrolling
Updated: 9/23/2011
Lovelace Sandia Health Systems Dept of Hematology
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
Single Arm, Non Randomized Phase II Trial of Gemcitabine and Oxaliplatin (GEM-OX) for Hepatocellular Carcinoma (HCC) Patients With Platelet Counts Greater Than 100,000 Per Microliter.
Status: Enrolling
Updated:  9/23/2011
University of New Mexico
mi
from
Albuquerque, NM
Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
Single Arm, Non Randomized Phase II Trial of Gemcitabine and Oxaliplatin (GEM-OX) for Hepatocellular Carcinoma (HCC) Patients With Platelet Counts Greater Than 100,000 Per Microliter.
Status: Enrolling
Updated: 9/23/2011
University of New Mexico
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
Single Arm, Non Randomized Phase II Trial of Gemcitabine and Oxaliplatin (GEM-OX) for Hepatocellular Carcinoma (HCC) Patients With Platelet Counts Greater Than 100,000 Per Microliter.
Status: Enrolling
Updated:  9/23/2011
St. Vincent Regional Medical Center
mi
from
Santa Fe, NM
Gemcitabine and Oxaliplatin for Hepatocellular Carcinoma With Platelet Counts Greater Than 100,000 Per Microliter
Single Arm, Non Randomized Phase II Trial of Gemcitabine and Oxaliplatin (GEM-OX) for Hepatocellular Carcinoma (HCC) Patients With Platelet Counts Greater Than 100,000 Per Microliter.
Status: Enrolling
Updated: 9/23/2011
St. Vincent Regional Medical Center
mi
from
Santa Fe, NM
Click here to add this to my saved trials
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®) and Temsirolimus (Torisel®) in Patients With Advanced Hepatocellular Cancer
Status: Enrolling
Updated:  10/6/2011
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®) and Temsirolimus (Torisel®) in Patients With Advanced Hepatocellular Cancer
Status: Enrolling
Updated: 10/6/2011
Indiana University Melvin and Bren Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®) and Temsirolimus (Torisel®) in Patients With Advanced Hepatocellular Cancer
Status: Enrolling
Updated:  10/6/2011
Washington University School of Medicine
mi
from
Saint Louis, MO
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®) and Temsirolimus (Torisel®) in Patients With Advanced Hepatocellular Cancer
Status: Enrolling
Updated: 10/6/2011
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®) and Temsirolimus (Torisel®) in Patients With Advanced Hepatocellular Cancer
Status: Enrolling
Updated:  10/6/2011
Duke Univ Med Ctr
mi
from
Durham, NC
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®) and Temsirolimus (Torisel®) in Patients With Advanced Hepatocellular Cancer
Status: Enrolling
Updated: 10/6/2011
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®) and Temsirolimus (Torisel®) in Patients With Advanced Hepatocellular Cancer
Status: Enrolling
Updated:  10/6/2011
Vanderbilt University School of Medicine
mi
from
Nashville, TN
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer
Phase II Study of Pegylated Liposomal Doxorubicin (Doxil®) and Temsirolimus (Torisel®) in Patients With Advanced Hepatocellular Cancer
Status: Enrolling
Updated: 10/6/2011
Vanderbilt University School of Medicine
mi
from
Nashville, TN
Click here to add this to my saved trials
Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma
RAD 0901- Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated:  4/20/2012
UAB
mi
from
Birmingham, AL
Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma
RAD 0901- Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma
Status: Enrolling
Updated: 4/20/2012
UAB
mi
from
Birmingham, AL
Click here to add this to my saved trials
SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma
A Pilot Study of Yttrium-90 Microspheres (SIR-Spheres®) Therapy for the Treatment of Unresectable Hepatocellular Carcinoma
Status: Enrolling
Updated:  5/4/2012
Thomas Jefferson University [Kimmel Cancer Center]
mi
from
Philadelphia, PA
SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma
A Pilot Study of Yttrium-90 Microspheres (SIR-Spheres®) Therapy for the Treatment of Unresectable Hepatocellular Carcinoma
Status: Enrolling
Updated: 5/4/2012
Thomas Jefferson University [Kimmel Cancer Center]
mi
from
Philadelphia, PA
Click here to add this to my saved trials
SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma
A Pilot Study of Yttrium-90 Microspheres (SIR-Spheres®) Therapy for the Treatment of Unresectable Hepatocellular Carcinoma
Status: Enrolling
Updated:  5/4/2012
UPMC Liver Cancer Center
mi
from
Pittsburgh, PA
SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma
A Pilot Study of Yttrium-90 Microspheres (SIR-Spheres®) Therapy for the Treatment of Unresectable Hepatocellular Carcinoma
Status: Enrolling
Updated: 5/4/2012
UPMC Liver Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma
A Pilot Study of Yttrium-90 Microspheres (SIR-Spheres®) Therapy for the Treatment of Unresectable Hepatocellular Carcinoma
Status: Enrolling
Updated:  5/4/2012
The Liver Institute at Methodist Dallas
mi
from
Dallas, TX
SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma
A Pilot Study of Yttrium-90 Microspheres (SIR-Spheres®) Therapy for the Treatment of Unresectable Hepatocellular Carcinoma
Status: Enrolling
Updated: 5/4/2012
The Liver Institute at Methodist Dallas
mi
from
Dallas, TX
Click here to add this to my saved trials
SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma
A Pilot Study of Yttrium-90 Microspheres (SIR-Spheres®) Therapy for the Treatment of Unresectable Hepatocellular Carcinoma
Status: Enrolling
Updated:  5/4/2012
M.D. Anderson Cancer Center
mi
from
Houston, TX
SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma
A Pilot Study of Yttrium-90 Microspheres (SIR-Spheres®) Therapy for the Treatment of Unresectable Hepatocellular Carcinoma
Status: Enrolling
Updated: 5/4/2012
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Electromagnetic Tracking of Devices During Biopsy Procedures
Electromagnetic Tracking of Devices During Biopsy Procedures
Status: Enrolling
Updated:  5/14/2012
Mount Sinai Hospital
mi
from
New York, NY
Electromagnetic Tracking of Devices During Biopsy Procedures
Electromagnetic Tracking of Devices During Biopsy Procedures
Status: Enrolling
Updated: 5/14/2012
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
PII of SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
Phase II Study of Stereotactic Body Radiotherapy (SBRT) and Chemotherapy for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
Status: Enrolling
Updated:  7/9/2012
Stanford University School of Medicine
mi
from
Stanford, CA
PII of SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
Phase II Study of Stereotactic Body Radiotherapy (SBRT) and Chemotherapy for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
Status: Enrolling
Updated: 7/9/2012
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
BKM120 in Cancers With PIK3CA Activating Mutations
An Open Label, Phase II Trial of BKM120 in Cancers With PIK3CA Activating Mutations
Status: Enrolling
Updated:  7/12/2012
Massachusetts General Hospital
mi
from
Boston, MA
BKM120 in Cancers With PIK3CA Activating Mutations
An Open Label, Phase II Trial of BKM120 in Cancers With PIK3CA Activating Mutations
Status: Enrolling
Updated: 7/12/2012
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
UCLA Medical Center-The Pfleger Liver Institute
mi
from
Los Angeles, CA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
UCLA Medical Center-The Pfleger Liver Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
UC San Diego
mi
from
San Diego, CA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
UC San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
University of California, San Francisco
mi
from
San Francisco, CA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
University of California, San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
University of Colorado Hospital
mi
from
Aurora, CO
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
University of Colorado Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
University of Miami
mi
from
Miami, FL
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Mount Sinai Medical Center
mi
from
Miami Beach, FL
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Mount Sinai Medical Center
mi
from
Miami Beach, FL
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Lahey Clinic Medical Center
mi
from
Burlington, MA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Lahey Clinic Medical Center
mi
from
Burlington, MA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Henry Ford Hospital
mi
from
Detroit, MI
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials